Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iradimed (IRMD) Current Deferred Revenue (2016 - 2025)

Historic Current Deferred Revenue for Iradimed (IRMD) over the last 13 years, with Q3 2025 value amounting to $3.2 million.

  • Iradimed's Current Deferred Revenue rose 2359.82% to $3.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.2 million, marking a year-over-year increase of 2359.82%. This contributed to the annual value of $2.3 million for FY2024, which is 1209.11% down from last year.
  • Iradimed's Current Deferred Revenue amounted to $3.2 million in Q3 2025, which was up 2359.82% from $3.3 million recorded in Q2 2025.
  • Iradimed's 5-year Current Deferred Revenue high stood at $3.4 million for Q4 2022, and its period low was $1.6 million during Q3 2022.
  • Over the past 5 years, Iradimed's median Current Deferred Revenue value was $2.5 million (recorded in 2024), while the average stood at $2.5 million.
  • In the last 5 years, Iradimed's Current Deferred Revenue soared by 5873.95% in 2021 and then tumbled by 3505.42% in 2022.
  • Iradimed's Current Deferred Revenue (Quarter) stood at $2.6 million in 2021, then surged by 32.12% to $3.4 million in 2022, then decreased by 23.8% to $2.6 million in 2023, then fell by 12.09% to $2.3 million in 2024, then surged by 39.76% to $3.2 million in 2025.
  • Its last three reported values are $3.2 million in Q3 2025, $3.3 million for Q2 2025, and $2.6 million during Q1 2025.